GSK0660 enhances antitumor immunotherapy by reducing PD-L1 expression

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• PD-1/PD-L1 immune checkpoint blockade is a key cancer therapy, but patient response rates remain low.
• The role of peroxisome-proliferator-activated receptor delta (PPARδ) in tumor immune escape is not well understood.
• PPARδ influences cell proliferation, inflammation, and tumor progression.

Purpose of the Study:

• To investigate the effect of PPARδ on PD-L1 expression in colon cancer.
• To evaluate the potential of PPARδ antagonism as a strategy to enhance cancer immunotherapy.

Main Methods:

• Utilized GSK0660, a PPARδ antagonist, in colon cancer cell lines.
• Assessed PD-L1 protein and gene expression using various assays.
• Performed luciferase reporter assays to analyze gene transcription activity.
• Evaluated T cell activity and tumor immune escape in an implanted tumor model.

Main Results:

• GSK0660 significantly reduced PD-L1 protein and gene expression in colon cancer cells.
• GSK0660 decreased PD-L1 gene transcription activity in a PPARδ-dependent manner.
• Reduced PD-L1 expression led to increased T cell activity and inhibited tumor immune escape.
• Combination therapy of GSK0660 and PD-1 antibody enhanced colorectal cancer immunotherapy.

Conclusions:

• PPARδ antagonism, specifically with GSK0660, effectively reduces PD-L1 expression in colon cancer.
• GSK0660 shows promise in overcoming immune escape mechanisms in cancer.
• Combined GSK0660 and PD-1 blockade represents a potential strategy to improve colorectal cancer immunotherapy outcomes.